title: Should we lower lipids in nonalcoholic fatty liver disease?
authors: Department of Hepatic Medicine, Australian National University Medical School, The Canberra Hospital, Woden, ACT, Australia. Electronic address: geoff.farrell@anu.edu.au.
authors: Geoffrey
authors: G
authors: Farrell
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D005234:Fatty Liver / Q000188:drug therapy*; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease
chemical_list: D000924:Anticholesteremic Agents
keywords: 3-hydroxy-3-methylglutaryl–coenzyme A; ALT; FC; GREACE; Greek Artorvastatin and Coronary Heart Disease Evaluation; HDL; HMGCoA; LDL; NAFLD; NASH; T2D; alanine aminotransferase; free cholesterol; high-density lipoprotein; low-density lipoprotein; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; type 2 diabetes